Study S002006

Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT05788601
Acronym: DREAM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 54
Start: 2023-04-27
Primary completion: 2024-04-24
Lead sponsor: University Hospital, Gentofte, Copenhagen
Conditions: Obesity; Inflammation
Interventions: DRUG:Dapiglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:2022-501649-54-00

Registered primary outcomes

Percentage change in body weight (kg) [From week 0 (baseline) to week 12 (end of treatment)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011013	Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial. Nielsen CK, EClinicalMedicine	2026	Randomized trial	PMID 41768273 DOI	cites ClinicalTrials.gov:NCT05788601; cites CTIS:2022-501649-54-00; registry reference DERIVED:41768273